Conestoga Capital Advisors LLC Has $176.13 Million Stake in Stevanato Group S.p.A. (NYSE:STVN)

Conestoga Capital Advisors LLC lifted its holdings in Stevanato Group S.p.A. (NYSE:STVN - Free Report) by 5.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 8,082,996 shares of the company's stock after purchasing an additional 407,086 shares during the quarter. Stevanato Group comprises 2.3% of Conestoga Capital Advisors LLC's holdings, making the stock its 16th biggest position. Conestoga Capital Advisors LLC owned approximately 2.67% of Stevanato Group worth $176,128,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Jennison Associates LLC bought a new stake in shares of Stevanato Group during the fourth quarter worth $20,239,000. SG Americas Securities LLC increased its holdings in Stevanato Group by 18.2% during the 4th quarter. SG Americas Securities LLC now owns 15,546 shares of the company's stock worth $339,000 after purchasing an additional 2,389 shares in the last quarter. AMI Asset Management Corp bought a new position in Stevanato Group during the 4th quarter worth about $1,089,000. Pier Capital LLC raised its stake in shares of Stevanato Group by 44.5% in the 3rd quarter. Pier Capital LLC now owns 370,997 shares of the company's stock valued at $7,420,000 after purchasing an additional 114,210 shares during the period. Finally, Kensington Investment Counsel LLC bought a new stake in shares of Stevanato Group in the third quarter valued at about $1,308,000.

Stevanato Group Stock Up 2.5 %

Shares of Stevanato Group stock traded up €0.54 ($0.56) on Thursday, reaching €22.47 ($23.41). 137,400 shares of the company were exchanged, compared to its average volume of 342,271. Stevanato Group S.p.A. has a one year low of €16.56 ($17.25) and a one year high of €34.73 ($36.18). The company has a current ratio of 1.81, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. The company has a 50-day moving average of €21.90 and a 200 day moving average of €20.53. The company has a market capitalization of $6.80 billion, a price-to-earnings ratio of 47.81, a PEG ratio of 7.76 and a beta of 0.56.

Stevanato Group (NYSE:STVN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported €0.12 ($0.13) EPS for the quarter, missing analysts' consensus estimates of €0.13 ($0.14) by (€0.01) (($0.01)). The firm had revenue of €277.90 million during the quarter, compared to analyst estimates of €274.36 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The business's revenue was up 2.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.16 EPS. On average, equities research analysts forecast that Stevanato Group S.p.A. will post 0.5 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on STVN shares. Bank of America lifted their target price on Stevanato Group from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, December 13th. Wolfe Research began coverage on shares of Stevanato Group in a report on Friday, December 13th. They issued an "outperform" rating and a $28.00 price objective on the stock. Finally, Morgan Stanley restated an "equal weight" rating and set a $23.00 target price (down previously from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Stevanato Group has a consensus rating of "Moderate Buy" and an average target price of €28.60 ($29.79).

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.